A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 272 participants.
Also called NCT06256549
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 272 participants
- Registry
-
NCT06256549
-
- Other papers using this trial's data
- Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT06256549. Randomized; no masking; primary purpose treatment. Start 2023-08-09 (actual); primary completion 2024-07-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- GZR18
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
Record details
- Record id
cardio:ct-nct06256549- Content hash
4ccfa9b40f05b2d3875b37a5599541e50e5a5180f1a584fafc0388a64aafffc3